AWY0 Stock Overview
Engages in the research and development of novel antisense pharmaceuticals in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Percheron Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.004 |
| 52 Week High | AU$0.084 |
| 52 Week Low | AU$0.0005 |
| Beta | 0.90 |
| 1 Month Change | -89.61% |
| 3 Month Change | -93.08% |
| 1 Year Change | -86.84% |
| 3 Year Change | -96.80% |
| 5 Year Change | n/a |
| Change since IPO | -96.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| AWY0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 700.0% | 2.2% | 0.7% |
| 1Y | -86.8% | -16.8% | 8.4% |
Return vs Industry: AWY0 underperformed the German Pharmaceuticals industry which returned -16.2% over the past year.
Return vs Market: AWY0 underperformed the German Market which returned 8.4% over the past year.
Price Volatility
| AWY0 volatility | |
|---|---|
| AWY0 Average Weekly Movement | 240.3% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AWY0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AWY0's weekly volatility has increased from 116% to 240% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | James Garner | www.PercheronTx.com |
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company’s product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial.
Percheron Therapeutics Limited Fundamentals Summary
| AWY0 fundamental statistics | |
|---|---|
| Market cap | €5.12m |
| Earnings (TTM) | -€7.20m |
| Revenue (TTM) | €1.79m |
2.9x
P/S Ratio-0.7x
P/E RatioIs AWY0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AWY0 income statement (TTM) | |
|---|---|
| Revenue | AU$2.97m |
| Cost of Revenue | AU$62.15k |
| Gross Profit | AU$2.91m |
| Other Expenses | AU$14.83m |
| Earnings | -AU$11.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.011 |
| Gross Margin | 97.91% |
| Net Profit Margin | -401.57% |
| Debt/Equity Ratio | 0% |
How did AWY0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 08:54 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Percheron Therapeutics Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Iain Wilkie | Morgans Financial Limited |
| Dr Storey | Wilsons Advisory and Stockbroking Ltd. |